About us

Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are exploring the hidden depths of cancer and T-cell biology to discover and characterize unconventional immunotherapy targets, such as MR1-presented ligands and Dark Antigens™, which arise from the altered cellular processes in cancer cells.

Enara Bio is backed by leading life science investors, including RA Capital, Samsara Biocapital and SV Health Investors. We collaborate with a number of world class academic institutions including the Francis Crick Institute, Cardiff University, Johns Hopkins School of Medicine and the University of Oxford, to help drive our differentiated science.

Enara Bio Our Story Poster

The Team

Andrew Fadden
Vice President, Corporate Development
Kevin Pojasek
President and Chief Executive Officer
David Watson
Chief Operating Officer
Sophie Papa
Chief Medical Officer
Erik Rutjens
Vice President, Cell Therapy Operations
Joseph Dukes
Vice President, Head of Research
Lucy Gallacher (Research Associate), Daniella Colbourne (Technician), Tatiana Lobry (Scientist), Nathifa Moyo (Senior Scientist), Angharad Lloyd (Associate Director, Immunology),
David Watson (Chief Operating Officer), Andrew Fadden (Vice President, Corporate Development), Kevin Pojasek (President and Chief Executive Officer), Joe Dukes (Vice President, Head of Research), Sophie Papa (Chief Medical Officer), Erik Rutjens (Vice President, Cell Therapy Operations)
Charlotte Howard (Associate Director, Corporate and Executive Administration)
Colin Moore (Senior Scientist), Charlotte Chapman (Senior Scientist), Mengqiu Li (Senior Scientist)
Kate Fynes (Cell Process Development Lead, Principal Scientist), Assa Oumie (Principal Scientist), Selsabil Dhaouadi (Scientist)
Jo Senra (Associate Director, Preclinical Validation), Veronica Freire-Beneitez (Senior Scientist), Vicki Jefferson (Scientist)
Rachel Abbott (Head of TCR Pipeline and Dark Antigen Research)
Emily Lam (Senior Scientist), Duncan Howie (Director of Immunology), Suzanne Cole (Principal Scientist),
Luke Williams (Senior Director, Biology)
Beth Turner (Head of Product and Pipeline Project Management), Simon Jarvis (IT Director), Kate Nicholson (Head of Business Operations), Jonathon Dines (Finance Director), Ray Duffy (Associate Director, Facilities and EHS)
Ron Wolchinsky (Associate Director, Molecular Immunology), Giulia Masi (Principal Scientist)
Adam Taylor (Senior Director, Business Insights and Strategy), Andrew Fadden (Vice President, Corporate Development), Jonathan Porter (Director, Intellectual Property), Hayden Selvadurai (Director, Corporate Development)
Stephane Lameynardie (Director, Cell Therapy Operations and Supply Chain)
Duncan Howie (Director, Immunology)
Rayner Queiroz (Senior Scientist), Fabio Marino (Associate Director, Immunopeptidomics), Rose Gathungu (Principal Scientist)
Jon Silk (Director, MR1 Research), Duncan Howie (Director, Immunology), Joe Dukes (Vice President, Head of Research), Rachel Abbott (Head of TCR Pipeline and Dark Antigen Research), Luke Williams (Senior Director, Biology),
Sophie Papa (Chief Medical Officer), Joseph Dukes (Vice President, Head of Research)
Jon Silk (Director, MR1 Research)
Eleanor Denham (Scientist), Phyllis Tea (Research Associate)
Ron Wolchinsky (Associate Director, Molecular Immunology)
Prathiba Kurupati (Senior Scientist), Jo Senra (Associate Director, Preclinical Validation), Veronica Freire-Beneitez (Senior Scientist), Vicki Jefferson (Scientist), Emily Tye (Research Associate)
Adam Taylor (Senior Director, Business Insights and Strategy), Andrew Fadden (Vice President, Corporate Development)
Stephane Lameynardie (Director, Cell Therapy Operations and Supply Chain), Erik Rutjens (Vice President, Cell Therapy Operations)
Emily Lam (Senior Scientist), Suzanne Cole (Principal Scientist), Phyllis Tea (Research Associate), Terri Cornforth (Principal Scientist), Eleanor Denham (Scientist), Duncan Howie (Director of Immunology)

Board of Directors

Scientific Advisory Board

Houman Ashrafian

Chairperson and co-founder

Houman is a Managing Partner at SV Health Investors and co-founded Enara Bio in 2016.

He has founded four SV portfolio companies. Alongside Enara Bio, this includes TRex Bio, a discovery stage company focused on the functional manipulation of T-regs in a tissue-specific and disease-specific fashion to deliver transformative therapies for multiple diseases. Houman is currently a director at TRex Bio, Sytrix, Zarodex Therapeutics and Karus Therapeutics. Houman also serves on the Dementia Discovery Fund (DDF) Investment Committee. Prior to joining SV, Houman co-founded the services company Cardiac Report in 2003, as well as Heart Metabolics in 2008. He went on to become Vice President and Head of the Clinical Science Group at UCB.

Houman is a cardiologist by training, gaining his BM BCh and a DPhil, from the University of Oxford. He was appointed as an Honorary Consultant Cardiologist at the John Radcliffe Hospital in Oxford in 2011. He is also Visiting Professor and head of Experimental Therapeutics at the University of Oxford.